Intra-Cellular Therapies (NASDAQ:ITCI) Shares Unloaded Rep. Josh Gottheimer

Representative Josh Gottheimer (D-New Jersey) recently sold shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). In a filing disclosed on February 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Intra-Cellular Therapies stock on January 24th. The trade occurred in the Representative’s “MORGAN STANLEY – SELECT UMA ACCOUNT # 1” account.

Representative Josh Gottheimer also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 1/31/2025.
• Sold $1,001 – $15,000 in shares of Arista Networks (NYSE:ANET) on 1/31/2025.
• Purchased $1,001 – $15,000 in shares of Visa (NYSE:V) on 1/31/2025.
• Purchased $1,001 – $15,000 in shares of Tesla (NASDAQ:TSLA) on 1/31/2025.
• Purchased $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 1/31/2025.
• Purchased $1,001 – $15,000 in shares of Twilio (NYSE:TWLO) on 1/31/2025.
• Sold $1,001 – $15,000 in shares of ICF International (NASDAQ:ICFI) on 1/31/2025.
• Purchased $1,001 – $15,000 in shares of Mastercard (NYSE:MA) on 1/31/2025.
• Purchased $1,001 – $15,000 in shares of Visa (NYSE:V) on 1/30/2025.
• Purchased $1,001 – $15,000 in shares of 3M (NYSE:MMM) on 1/30/2025.

Intra-Cellular Therapies Price Performance

ITCI stock opened at $127.56 on Wednesday. The firm has a 50-day moving average of $102.37 and a 200 day moving average of $86.66. The company has a market cap of $13.56 billion, a P/E ratio of -146.62 and a beta of 0.72. Intra-Cellular Therapies, Inc. has a 1 year low of $62.78 and a 1 year high of $128.00.

Analyst Upgrades and Downgrades

ITCI has been the subject of a number of research analyst reports. Leerink Partnrs lowered shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. Needham & Company LLC reiterated a “hold” rating and set a $100.00 target price on shares of Intra-Cellular Therapies in a research note on Monday, January 13th. Piper Sandler reissued a “neutral” rating and set a $132.00 price target (up from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Canaccord Genuity Group downgraded shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and boosted their price objective for the company from $119.00 to $132.00 in a research report on Friday, January 31st. Finally, Cantor Fitzgerald raised shares of Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 14th. Nine investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $103.62.

Insider Transactions at Intra-Cellular Therapies

In other Intra-Cellular Therapies news, CEO Sharon Mates sold 51,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the sale, the chief executive officer now owns 1,070,329 shares of the company’s stock, valued at approximately $91,834,228.20. The trade was a 4.55 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 2.60% of the company’s stock.

Institutional Trading of Intra-Cellular Therapies

Institutional investors and hedge funds have recently modified their holdings of the stock. CWM LLC lifted its position in shares of Intra-Cellular Therapies by 867.5% in the 3rd quarter. CWM LLC now owns 13,274 shares of the biopharmaceutical company’s stock worth $971,000 after purchasing an additional 11,902 shares during the period. Inspire Investing LLC raised its stake in Intra-Cellular Therapies by 10.4% in the third quarter. Inspire Investing LLC now owns 5,606 shares of the biopharmaceutical company’s stock worth $410,000 after buying an additional 528 shares in the last quarter. Essex Investment Management Co. LLC lifted its holdings in Intra-Cellular Therapies by 85.7% during the third quarter. Essex Investment Management Co. LLC now owns 58,385 shares of the biopharmaceutical company’s stock worth $4,272,000 after buying an additional 26,937 shares during the period. nVerses Capital LLC bought a new stake in Intra-Cellular Therapies during the 3rd quarter valued at $285,000. Finally, Raymond James & Associates increased its holdings in shares of Intra-Cellular Therapies by 2.8% in the 3rd quarter. Raymond James & Associates now owns 158,852 shares of the biopharmaceutical company’s stock valued at $11,623,000 after acquiring an additional 4,325 shares during the period. Institutional investors own 92.33% of the company’s stock.

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey’s 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027.

Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey’s 5th Congressional District. He declared candidacy for the 2026 election.

Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025.

Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.